Trial results

Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder

NCT07523633 on ClinicalTrials.gov · last registry update 2026-05-14

Recruiting now, toward 100 participants. Due to report 30 April 2028, alongside 27 other tracked readouts that quarter. Primary outcome, as filed: Cannabis consumption. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for substance use — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status

RECRUITING

Phase

P2

Drug

semaglutide

Rybelsus, Wegovy, Ozempic

Sponsor

Anders Fink-Jensen, MD, DMSci

Sponsor type

Other

Enrollment

100

Started

2026-04-30

Primary completion

2028-04-30 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Cannabis consumption

Conditions studied

Cannabis Use Disorder · Cannabis Use Disorders · Cannabis Abuse · Cannabis Dependence · Cannabis Addiction

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.